Alnylam Pharmaceuticals (LTS:0HD2) Accumulated Depreciation : $0 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Alnylam Pharmaceuticals Accumulated Depreciation?

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Alnylam Pharmaceuticals's quarterly accumulated depreciation increased from Sep. 2023 ($0 Mil) to Dec. 2023 ($-223 Mil) but then stayed the same from Dec. 2023 ($-223 Mil) to Mar. 2024 ($0 Mil).

Alnylam Pharmaceuticals's annual accumulated depreciation increased from Dec. 2021 ($-140 Mil) to Dec. 2022 ($-173 Mil) and increased from Dec. 2022 ($-173 Mil) to Dec. 2023 ($-223 Mil).

Alnylam Pharmaceuticals Accumulated Depreciation Historical Data

The historical data trend for Alnylam Pharmaceuticals's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alnylam Pharmaceuticals Accumulated Depreciation Chart

Alnylam Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accumulated Depreciation

Get a 7-Day Free Trial

-76.16

-104.35

-140.42

-173.45

-223.08

Alnylam Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accumulated Depreciation	Get a 7-Day Free Trial															-	-	-	-223.08	-

Alnylam Pharmaceuticals Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

Alnylam Pharmaceuticals Accumulated Depreciation Related Terms

Thank you for viewing the detailed overview of Alnylam Pharmaceuticals's Accumulated Depreciation provided by GuruFocus.com. Please click on the following links to see related term pages.

Alnylam Pharmaceuticals (LTS:0HD2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alnylam Pharmaceuticals Inc (LTS:0HD2) » Definitions » Accumulated Depreciation

Comparable Companies

Traded in Other Exchanges

ALNY:USA ALNY:Mexico DUL:Germany

Address

675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142

Website

https://www.alnylam.com

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Alnylam Pharmaceuticals (LTS:0HD2) Headlines

No Headlines